XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Statements of Operations - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Operating expenses:        
Research and development $ 1,380,801 $ 718,898 $ 5,594,886 $ 1,641,822
General and administrative 1,472,969 884,859 3,022,244 3,088,726
Total operating expenses 2,853,770 1,603,757 8,617,130 4,730,548
Operating loss (2,853,770) (1,603,757) (8,617,130) (4,730,548)
Other income (expense):        
Change in fair value of derivative liability       (26,500)
Interest income, net 5,554 10,500 7,885 47,012
Grant income   586,903 36,754 952,602
Total other income (expense) 5,554 597,403 44,639 973,114
Loss before income taxes (2,848,216) (1,006,354) (8,572,491) (3,757,434)
Income tax expense (benefit) 0   0  
Net loss $ (2,848,216) $ (1,006,354) $ (8,572,491) $ (3,757,434)
Basic loss per common share $ (0.35) $ (0.15) $ (1.15) $ (0.61)
Diluted loss per common share $ (0.35) $ (0.15) $ (1.15) $ (0.61)
Weighted average number of common shares outstanding, basic 8,099,103 6,871,554 7,466,443 6,113,400
Weighted average number of common shares outstanding, diluted 8,099,103 6,871,554 7,466,443 6,113,400